Review

The colorectal cancer immune microenvironment and approach to immunotherapies

Division of Gastroenterology, Department of Internal Medicine & Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

John M Carethers

*Author for correspondence: Tel.: +1 734 615 1717; Fax: +1 734 936 7024;

E-mail Address: jcarethe@umich.edu

Division of Gastroenterology, Department of Internal Medicine & Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA

Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

Published Online:22 Aug 2017https://doi.org/10.2217/fon-2017-0145

View article

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).Crossref, Medline, CAS, Google Scholar
2 Siegel RL, Miller KD, Fedewa SA et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67(3), 177–193 (2017).Crossref, Medline, Google Scholar
3 Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654–2666 (2005).Crossref, Medline, CAS, Google Scholar
4 Galon J, Costes A, Sanches-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960–1964 (2006).Crossref, Medline, CAS, Google Scholar
5 Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69(6), 2685–2693 (2009).Crossref, Medline, CAS, Google Scholar
6 Pages F, Kirilovsky A, Melecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27(35), 5944–5951 (2009).Crossref, Medline, CAS, Google Scholar
7 Tosolini M, Kirilovsky A, Mlecnik B et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 71(4), 1263–1271 (2011).Crossref, Medline, CAS, Google Scholar
8 Mlecnik B, Bindea G, Kirilovsky A et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 8(327), 327ra26 (2016). •• Describes the use of the immunoscore, and how it may be better than stage or microsatellite instable classification.Crossref, Medline, Google Scholar
9 Becht E, de Reyniès A, Giraldo NA et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22(16), 4057–4066 (2016).Crossref, Medline, CAS, Google Scholar
10 Galon J, Pages F, Marincola FM et al. Cancer classification using the immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).Crossref, Medline, Google Scholar
11 Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375(19), 1845–1855 (2016).Crossref, Medline, CAS, Google Scholar
12 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012). •• Initial clinical trial data and demonstration of the effectiveness of PD-1 blockade for cancer.Crossref, Medline, CAS, Google Scholar
13 Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).Crossref, Medline, CAS, Google Scholar
14 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015). •• Initial description of use of PD-1 inhibitor and specific response in patients with microsatellite instability colorectal cancers (CRCs).Crossref, Medline, CAS, Google Scholar
15 MacCarty WC. Factors which influences longevity in cancer. Ann. Surg. 76, 9–12 (1922).Medline, CAS, Google Scholar
16 Underwood JCE. Lymphoreticular infiltration in human tumors: prognostic and biological implications: a review. Br. J. Cancer 30, 538–548 (1974).Crossref, Medline, CAS, Google Scholar
17 Murray D, Hreno A, Dutton J, Hampson LG. Prognosis in colon cancer A pathologic reassessment. Arch. Surg. 110, 908–913 (1975).Crossref, Medline, CAS, Google Scholar
18 Watt AG, House AK. Colonic carcinoma A quantitative assessment of lymphocyte infiltration at periphery of colonic tumors related to prognosis. Cancer 41, 279–282 (1978).Crossref, Medline, CAS, Google Scholar
19 Engel P, Boumsell L, Balderas R et al. CD nomenclature 2015: human leukocyte differentiation antigen workshops as a driving force in immunology. J. Immunol. 195, 4555–4563 (2015).Crossref, Medline, CAS, Google Scholar
20 Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989–995 (1987).Medline, CAS, Google Scholar
21 Gallagher P, Vose BM, Moore M, Schofield PF. Role of autologous lymphocyte cytotoxicity in colonic neoplasia. Gut 23, 31–35 (1982).Crossref, Medline, CAS, Google Scholar
22 Ebert EC, Brolin RE, Roberts AI. Characterization of activated lymphocytes in colon cancer. Clin. Immunol. Immunopathol. 50(1 Pt 1), 72–81 (1989).Crossref, Medline, CAS, Google Scholar
23 Vose BM, Moor M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int. J. Cancer 24, 579–585 (1979).Crossref, Medline, CAS, Google Scholar
24 Holmes EC. Immunology of tumor infiltrating lymphocytes. Ann. Surg. 201, 158–163 (1985).Crossref, Medline, CAS, Google Scholar
25 Jass JR. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 39, 585–589 (1986).Crossref, Medline, CAS, Google Scholar
26 Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 15(20), 6412–6420 (2009).Crossref, Medline, CAS, Google Scholar
27 Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480–483 (1998).Crossref, Medline, CAS, Google Scholar
28 Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2(6), 401–409 (2002).Crossref, Medline, CAS, Google Scholar
29 Naito Y, Saito K, Shiiba K et al. CD8⁺ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491–3494 (1998).Medline, CAS, Google Scholar
30 Mlecnik B, Tosolini M, Charoentong P et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4), 1429–1440 (2010).Crossref, Medline, CAS, Google Scholar
31 Rozek LS, Schmit SL, Greenson JK et al. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J. Natl Cancer Inst. 108(8), djw027 (2016).Crossref, Google Scholar
32 Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610–618 (2011).Crossref, Medline, Google Scholar
33 Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4), 782–795 (2013).Crossref, Medline, CAS, Google Scholar
34 Angelova M, Charoentong P, Hackl H et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).Crossref, Medline, Google Scholar
35 Bronte Vincenzo, Brandau Sven, Chen Shu-Hsia et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).Crossref, Medline, CAS, Google Scholar
36 OuYang LY, Wu XJ, Ye SB et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J. Transl. Med. 13, 47 (2015).Crossref, Medline, Google Scholar
37 Dalton DK, Noelle RJ. The roles of mast cells in anticancer immunity. Cancer Immunol. Immunother. 61(9), 1511–1520 (2012).Crossref, Medline, CAS, Google Scholar
38 Yodavudh S, Tangjitgamol S, Puangsa-art S. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J. Med. Assoc. Thai. 91, 723–732 (2008).Medline, Google Scholar
39 Amicarella F, Muraro MG, Hirt C et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 66, 692–704 (2015).Crossref, Medline, Google Scholar
40 De Simone M, Arrigoni A, Rossetti G et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45(5), 1135–1147 (2016).Crossref, Medline, CAS, Google Scholar
41 Torres S, Bartolomé RA, Mendes M et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin. Cancer Res. 19(21), 6006–6019 (2013).Crossref, Medline, CAS, Google Scholar
42 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).Crossref, Medline, Google Scholar
43 Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149, 1177–1190 (2015).Crossref, Medline, CAS, Google Scholar
44 Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135, 1079–1099 (2008).Crossref, Medline, CAS, Google Scholar
45 Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes 6, 185–205 (2015).Crossref, Medline, CAS, Google Scholar
46 Koi M, Umar A, Chauhan DP et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N’-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308–4314 (1994).Medline, CAS, Google Scholar
47 Carethers JM, Hawn MT, Chauhan DP et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N’-nitro-N-nitrosoguanidine. J. Clin. Invest. 98, 199–206 (1996).Crossref, Medline, CAS, Google Scholar
48 Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J. Gastroenterol. 21, 9253–9261 (2015).Crossref, Medline, CAS, Google Scholar
49 Carethers JM. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13(1), 73–80 (2017). •• Overview of microsatellite instability in CRCs and multiple clinic pathological correlates including immune response.Crossref, Medline, Google Scholar
50 Schwitalle Y, Kloor M, Eiermann S et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134, 988–997 (2008).Crossref, Medline, CAS, Google Scholar
51 Tseng-Rogenski SS, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS ONE 7(11), e50616 (2012).Crossref, Medline, CAS, Google Scholar
52 Tseng-Rogenski SS, Hamaya Y, Choi DY, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 148(3), 579–589 (2015). •• Demonstrates how inflammation can directly affect DNA repair in colon cancers.Crossref, Medline, CAS, Google Scholar
53 Campregher C, Schmid G, Ferk F et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS ONE 7(11), e50541 (2012).Crossref, Medline, CAS, Google Scholar
54 Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248–5257 (1988).Google Scholar
55 Hamaya Y, Guarinos C, Tseng-Rogenski SS et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS ONE 10, e0127591 (2015). •• Demonstrates the fidelity of DNA mismatch repair to recognize 5-fluorouracil for patient survival.Crossref, Medline, Google Scholar
56 Haugen AC, Goel A, Yamada K et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res. 68(20), 8465–8472 (2008).Crossref, Medline, CAS, Google Scholar
57 Yamada K, Kanazawa S, Koike J et al. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol. Rep. 23(2), 551–561 (2010).Medline, CAS, Google Scholar
58 Lee SY, Chung H, Devaraj B et al. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology 139(5), 1519–1525 (2010).Crossref, Medline, CAS, Google Scholar
59 Lee SY, Miyai K, Han HS et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig. Dis. Sci. 57(1), 72–78 (2012).Crossref, Medline, CAS, Google Scholar
60 Garcia M, Choi C, Kim HR et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 143(1), 48–50 (2012).Crossref, Medline, CAS, Google Scholar
61 Devaraj B, Lee A, Cabrera BL et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J. Gastrointest. Surg. 14, 1521–1528 (2010).Crossref, Medline, Google Scholar
62 Koi M, Garcia M, Choi C et al. Microsatellite alterations with allelic loss on 9p24.2 signify less aggressive colorectal cancer metastasis. Gastroenterology 150, 944–955 (2016). •• Demonstrates modulating genetic factors that can alter prognosis for patients with inflammatory (elevated microsatellite alterations at selected tetranucleotide repeats) CRCs.Crossref, Medline, CAS, Google Scholar
63 Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21(11), 1350–1356 (2015).Crossref, Medline, CAS, Google Scholar
64 Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609–618 (2005).Crossref, Medline, CAS, Google Scholar
65 Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3), 698–711 (2016).Crossref, Medline, CAS, Google Scholar
66 Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl Acad. Sci. USA 91(11), 4751–4755 (1994).Crossref, Medline, CAS, Google Scholar
67 Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int. J. Cancer 127(5), 1001–1010 (2010).Crossref, Medline, CAS, Google Scholar
68 Kloor M, Becker C, Benner A et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 65, 6418–6424 (2005).Crossref, Medline, CAS, Google Scholar
69 Giannakis M, Mu XJ, Shukla SA et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15(4), 857–865 (2016).Crossref, Medline, CAS, Google Scholar
70 Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu. Rev. Microbiol. 70, 395–411 (2016).Crossref, Medline, CAS, Google Scholar
71 Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nature Rev. Cancer 17, 271–286 (2017).Crossref, Medline, CAS, Google Scholar
72 Tahara T, Yamamoto E, Suzuki H et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74(5), 1311–1318 (2014).Crossref, Medline, CAS, Google Scholar
73 Nosho K, Sukawa Y, Adachi Y et al. Association of Fusobacteriumnucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 22(2), 557–566 (2016). Crossref, Medline, CAS, Google Scholar
74 Mima K, Nishihara R, Qian ZR et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973–1980 (2016).Crossref, Medline, CAS, Google Scholar
75 Dejea CM, Wick EC, Hechenbleikner EM et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl Acad. Sci. USA 111(51), 18321–18326 (2014).Crossref, Medline, CAS, Google Scholar
76 Mima K, Sukawa Y, Nishihara R et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1(5), 653–661 (2015).Crossref, Medline, Google Scholar
77 Kaplan CW, Ma X, Paranjpe A et al. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect. Immun. 78(11), 4773–4778 (2010).Crossref, Medline, CAS, Google Scholar
78 Kostic AD, Chun E, Robertson L et al. Fusobacteriumnucleatum potentiates intestinal tumorigenesis and modulates the tumor-immunemicroenvironment. Cell Host Microbe 14, 207–215 (2013).Crossref, Medline, CAS, Google Scholar
79 Gur C, Ibrahim Y, Isaacson B et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015).Crossref, Medline, CAS, Google Scholar
80 Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol. Ther. 8(23), 13–22 (2009).Crossref, Medline, Google Scholar
81 Calon A, Lonardo E, Berenguer-Llergo A et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47(4), 320–309 (2015). •• Describes consensus molecular subtypes of colon cancer, including the poor prognosis associated with cancer-associated fibroblast molecular signature.Crossref, Medline, CAS, Google Scholar
82 Giraldo NA, Becht E, Pagès F et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21(13), 3031–3040 (2015).Crossref, Medline, CAS, Google Scholar
83 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456), 43–49 (2013).Crossref, Medline, Google Scholar
84 Kitajima T, Koi M, Gutierrez L et al. Loss of heterozygosity (LOH) at the hypoxia inducible factor 3A (HIF3A) locus and loss of protein expression is acquired in colorectal cancer (CRC) metastasis. Gastroenterology 150(4), S366 (2016).Crossref, Google Scholar
85 Gradin K, Poellinger L, Yamamoto M. Regulation of hypoxia-inducible gene expression after HIF activation. Exp. Cell. Res. 356, 182–186 (2017).Crossref, Medline, Google Scholar
86 Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9, 561–570 (2012).Crossref, Medline, CAS, Google Scholar
87 Frouws MA, van Herk-Sukel MPP, Maas HA et al. The mortality reducing effect of aspirin in colorectal cancer patients: interpreting the evidence. Cancer Treat. Rev. 55, 120–127 (2017).Crossref, Medline, CAS, Google Scholar
88 Hamada T, Cao Y, Qian ZR et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J. Clin. Oncol. doi:10.1200/JCO.2016.70.7547 (2017) (Epub ahead of print).Crossref, Medline, Google Scholar
89 Gray RT, Cantwell MM, Coleman HG et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study. Clin. Transl. Gastroenterol. 8(4), e91 (2017).Crossref, Medline, Google Scholar
90 Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96(26), 15074–15079 (1999).Crossref, Medline, CAS, Google Scholar
91 Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353, 345–350 (1999).Crossref, Medline, CAS, Google Scholar
92 Uyl-de Groot CA, Vermorken JB, Hanna MG et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23, 2379–2387 (2005).Crossref, Medline, CAS, Google Scholar
93 de Weger VA, Turksma AW, Voorham QJ et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin. Cancer Res. 18(3), 882–889 (2012).Crossref, Medline, CAS, Google Scholar
94 Zhen YH, Liu XH, Yang Y et al. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol. Immunother. 64(9), 1083–1093 (2015).Crossref, Medline, CAS, Google Scholar
95 Mennonna D, Maccalli C, Romano MC et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut 66(3), 454–463 (2017).Crossref, Medline, CAS, Google Scholar
96 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco. Targets Ther. 9, 1899–1920 (2016).Crossref, Medline, CAS, Google Scholar
97 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).Crossref, Medline, CAS, Google Scholar
98 Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010).Crossref, Medline, CAS, Google Scholar
99 Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28(21), 3485–3490 (2010).Crossref, Medline, CAS, Google Scholar
100 Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010)Crossref, Medline, CAS, Google Scholar
101 Overman MJ, Kopetz S, McDermott RS et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J. Clin. Oncol. 34(Suppl.), Abstract 3501 (2016).Google Scholar
102 Bendell JC, Powderly JD, Lieu CH et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 33 (Suppl.) Abstract 704 (2015).Crossref, Google Scholar
103 Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74–88 (2013).Crossref, Medline, CAS, Google Scholar
104 Tesniere A, Schlemmer F, Boige V et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4), 482–491 (2010).Crossref, Medline, CAS, Google Scholar
105 Vincent J, Mignot G, Chalmin F et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052–3061 (2010).Crossref, Medline, CAS, Google Scholar
106 Kakarla S, Song XT, Gottschalk S. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4(11), 1129–1138 (2012).Link, CAS, Google Scholar
107 Cheng JD, Valianou M, Canutescu AA et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4(3), 351–360 (2005).Crossref, Medline, CAS, Google Scholar
108 Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639–1647 (2003).Medline, CAS, Google Scholar
109 Chen M, Xiang R, Wen Y et al. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci. Rep. 5, 14421 (2015).Crossref, Medline, CAS, Google Scholar

Vol. 13, No. 18

Metrics

Downloaded 922 times

History

Published online 22 August 2017

Published in print August 2017

Information

Keywords

Financial & competing interests disclosure

This work was supported by the United States Public Health Service (R01 DK067287, U01 CA162147 and R01 CA206010) and the A Alfred Taubman Medical Research Institute of the University of Michigan. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download